(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Viking Therapeutics stock fell Thursday after it reported a widening quarterly earnings loss—but that doesn’t mean it won’t eventually pose a threat to Eli Lilly and Novo Nordisk in the weight-loss ...

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...

Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

With the sales of weight-loss drugs booming, India is now the epicentre of the global obesity treatment market, reports The ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Rhythm Pharmaceuticals develops medicines for rare disorders that cause weight gain. The company's only approved product is ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers ...